Low dose antibody-based methods for treating hematologic malignancies
This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225 Ac-HuM195.
1. A method for treating relapsed and/or refractory acute myeloid leukemia in a human subject, comprising the step of:
intravenously administering a therapeutically effective dose of 225 Ac-labeled HuM195 to a human subject afflicted with relapsed and/or refractory acute myeloid leukemia, wherein the human subject has a peripheral blast burden below 200 blast cells/μl.
2. The method of claim 1 , further comprising the step of before administering the 225 Ac-labeled HuM195 to the human subject, determining that the human subject has a peripheral blast burden below 200 blast cells/μl.
3. The method of claim 1 , wherein the human subject is ineligible to receive high intensity chemotherapy.
4. The method of claim 2 , wherein the human subject is ineligible to receive high intensity chemotherapy.
5. The method of claim 1 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, administering low dose cytarabine to the human subject.
6. The method of claim 2 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, administering low dose cytarabine to the human subject.
7. The method of claim 3 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, administering low dose cytarabine to the human subject.
8. The method of claim 4 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, administering low dose cytarabine to the human subject.
9. The method of claim 1 , wherein the human subject's peripheral blast burden is 50 blast cells/μl or lower.
10. The method of claim 1 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, medically lowering the human subject's peripheral blast burden from at or above 200 blast cells/μl to below 200 blast cells/μl,
wherein the administering step is performed while the human subject's peripheral blast burden is still below 200 blast cells/μl.
11. The method of claim 10 , wherein the human subject's peripheral blast burden is medically lowered to 50 blast cells/μl or lower.
12. The method of claim 5 , further comprising the step of:
before administering the 225 Ac-labeled HuM195 to the human subject, medically lowering the human subject's peripheral blast burden from at or above 200 blast cells/μl to below 200 blast cells/μl,
wherein the administering step is performed while the human subject's peripheral blast burden is still below 200 blast cells/μl.
13. The method of claim 12 , wherein the human subject's peripheral blast burden is medically lowered to 50 blast cells/μl or lower.